Lubaba, A., & Fariha, L. M. (2024). PCSK9i: Proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment. Brac University.
Chicago-viite (17. p.)Lubaba, Anikah, ja Luluel Maknun Fariha. PCSK9i: Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor a New Phase of Lipid-lowering Treatment. Brac University, 2024.
MLA-viite (8. p.)Lubaba, Anikah, ja Luluel Maknun Fariha. PCSK9i: Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor a New Phase of Lipid-lowering Treatment. Brac University, 2024.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.